Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
746.82 K
Value Traded
1.45 M
Short % Float
0.65%
Days to Cover
1.0
-16.45%Week
-52.08%1 Month
-80.41%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
185.66 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
94.24 M
Float Shares
67.13 M
Insiders
13.30%
Institutions
25.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
GLAS Catalyst Timeline
Dated clinical, regulatory and corporate events for Glass House Brands Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Glass House Brands Inc.
36Total events
4Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 22
▲Other Regulator MilestoneEx-US Regulatory
Casitas and Padaro farms achieve PJRFSI GACP certification
▲Product LaunchPost-Market
Mama Sue Professional Athlete Balm launched for sale in California
●Other Regulator MilestoneEx-US Regulatory
Application for DEA Registration of Certain Medical Operations
●Management ChangeCorporate
Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
◆ATM ProgramCorporate
Filing of updated at-the-market distribution program for up to US$100 million
▲Timing GuidancePresentation
Full contribution from Greenhouse Two expected at end of Q3 2026
Past FDA Catalysts and PDUFA Decisions
How GLAS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every GLAS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tu WilliamOfficer (SVP, Corporate Controller) | Option | 38,691 42,474 held | $0.00 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GLAS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GLAS for Q2 2026. | ||||
Ownership Trends
GLAS Short Interest
Shares sold short, counted twice a month.
0.65%
Short % of Float
of tradable shares sold short
434.4K
Shares Sold Short
+14.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GLAS ranks across every disease it competes in
Competitive Position is a premium feature
See how GLAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGLAS News
-GLAS
Oct 19, 2026▼ -22.9%on this news
Glass House Brands Reports Preliminary Unaudited Third Quarter Financial Results and Resignation of John Nichols Jr. from Board of Directors
Glass House Brands reported preliminary financial results for Q3 2026, showing record biomass production and increased revenue. The company achieved $56.8 million in revenue and reduced production costs to $110 per pound. Despite these gains, operating cash flow remained negative. Additionally, John Nichols Jr. resigned from the Board of Directors.
Read more →-GLAS
Oct 14, 2026Glass House Brands Receives Good Agricultural and Collection Practice (GACP) Certifications
Glass House Brands has received Good Agricultural and Collection Practice (GACP) certifications for its Casitas and Padaro farms, marking a significant milestone for the company. This certification enables the company to supply cannabis to international medical markets, enhancing its growth potential. The facilities are among the largest GACP-certified operations in the U.S., supporting future export opportunities.
Read more →-GLAS
Sep 29, 2026Glass House Brands Announces Planned Retirement of Chief Financial Officer
Glass House Brands Inc. announced the planned retirement of CFO Mark Vendetti, effective March 31, 2027. Vendetti has been a key figure in the company's growth over the past five years. The company is now initiating a search for his successor to ensure a smooth transition during this period.
Read more →-GLAS
Sep 14, 2026Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California
Glass House Brands has launched the Mama Sue Professional Athlete Balm, its first topical product, in California. This balm utilizes proprietary transdermal technology and is designed for quick absorption and effective pain relief. Developed in collaboration with professional athletes, it aims to address everyday aches and pains. The product is now available at select licensed dispensaries.
Read more →-GLAS
Sep 4, 2026Glass House Brands to Participate in Upcoming September Investor Conferences
Glass House Brands Inc. announced its participation in several upcoming investor conferences in September 2026. The conferences include the ATB Cormark Capital Markets Life Sciences Fall Institutional Investor Conference, Lake Street Capital Markets Best Ideas Growth Conference, and H.C. Wainwright Global Investment Conference. Management will host one-on-one meetings with investors at these events to discuss the company's growth and strategies.
Read more →-GLAS
Aug 13, 2026▼ -5.6%on this news
Glass House Brands Reports Second Quarter 2026 Financial Results
Glass House Brands reported its second quarter 2026 financial results, highlighting record biomass production of 246,000 pounds and a cost of production of $122 per pound. The company has completed the deconsolidation of its retail operations and uplisted to the NYSE. Despite a slight decrease in revenue compared to the previous year, adjusted EBITDA turned positive at $5.7 million.
Read more →-GLAS
Aug 10, 2026Glass House Brands to Host Second Quarter 2026 Earnings Call on August 13, 2026
Glass House Brands Inc. will report its financial results for Q2 2026 on August 13, 2026, after market close. A conference call will be held at 5:00 p.m. ET to discuss these results. The company emphasizes its growth in the cannabis market and commitment to sustainability. Participants can access the live webcast or dial in for the call.
Read more →-GLAS
Jul 27, 2026Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
Glass House Brands has appointed Matt Murphy, a former DEA compliance executive, as an advisor to enhance its regulatory compliance for interstate commerce and medical cannabis exports. Murphy's expertise will help the company navigate the complexities of the Controlled Substances Act. The initiative aims to facilitate the secure distribution of cannabis products beyond California, targeting international markets.
Read more →-GLAS
Jul 15, 2026Glass House Brands Announces the Filing of an Updated At-The-Market Distribution Program
Glass House Brands Inc. has announced an update to its at-the-market distribution program, allowing the sale of up to $100 million in equity shares. This update enables sales in the U.S. following the company's recent NYSE listing. Proceeds from the program are intended for cultivation expansion and potential acquisitions, although market conditions may affect actual sales.
Read more →-GLAS
Jul 7, 2026Glass House Brands Completes First International Hemp Sale
Glass House Brands has completed its first international sale of smokeable CBD biomass to Europe, marking a significant milestone for the company. The product originates from the initial harvest of Greenhouse 4 at their Camarillo Farm, which is compliant with California regulations. The company aims to leverage this initial sale for future product development and expansion into the European market.
Read more →-GLAS
Jun 25, 2026Glass House Brands Announces Uplist to NYSE
Glass House Brands announced the approval of its subordinate voting shares for listing on the NYSE, effective June 30, 2026. This milestone follows the reclassification of medical cannabis to Schedule III, which opens up opportunities for interstate commerce and exports to Europe. The company aims to enhance its market presence and profitability.
Read more →-GLAS
Jun 24, 2026Glass House Brands Provides Notice of Warrant Acceleration
Glass House Brands announced the acceleration of expiry dates for its Series B, C, and D Warrants. This decision follows the company's share price closing at or above US$12.00 for the required trading days. Warrant holders now have until July 23, 2026, to exercise their warrants before they expire.
Read more →-GLAS
Jun 19, 2026Glass House Brands Announces Voting Results Following Annual Meeting
Glass House Brands Inc. announced the successful outcomes of its annual meeting held on June 18, 2026. Shareholders approved all resolutions, including the election of eight board nominees and the re-appointment of auditors Macias Gini & O'Connell LLP. The meeting reflects strong shareholder support for the company's leadership.
Read more →-GLAS
Jun 17, 2026Glass House Brands Announces its Deconsolidation of its Dual-Use Business and its Application for Uplisting of Shares to NYSE
Glass House Brands has applied to list its subordinate voting shares on the NYSE. This move follows the deconsolidation of its dual-use cannabis business from its medical cannabis operations. The deconsolidation allows for a clearer separation of business segments, potentially enhancing its market position.
Read more →-GLAS
Jun 11, 2026Glass House Brands Announces the Filing of Shelf Prospectus and At-The-Market Distribution Program
Glass House Brands has filed a new short form base shelf prospectus to replace its expiring one. The company also announced an at-the-market distribution program, allowing it to sell up to $100 million in equity shares. Proceeds from this program will support cultivation expansion and potential acquisitions.
Read more →-GLAS
May 29, 2026Glass House Brands Completes Previously Announced Warrant Redemption
Glass House Brands Inc. announced the successful completion of its warrant redemption on May 28, 2026. The company redeemed all remaining warrants under the Warrant Agency Agreement, totaling 30,644,500 warrants. This process resulted in the issuance of 362,401 shares to warrant holders, rounding to the nearest whole number.
Read more →-GLAS
May 20, 2026Glass House Brands to Host Investor Sesh V on Thursday, June 18, 2026
Glass House Brands will host its annual Investor Sesh V on June 18, 2026, at its Camarillo facility. This event allows shareholders to engage with the executive team and tour the largest cannabis farm in the U.S. Refreshments and products will be available for purchase. Registration details will follow.
Read more →-GLAS
May 18, 2026Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program
Glass House Brands filed a prospectus supplement related to its At-The-Market distribution program, aiming to sell up to US$50 million in equity shares. The proceeds will support cultivation expansion and potential acquisitions. This program is viewed as a long-term capital source, allowing for opportunistic access to funds.
Read more →-GLAS
May 13, 2026Glass House Brands Reports First Quarter 2026 Financial Results
Glass House Brands reported Q1 2026 financial results with revenue of $40.5 million, down from $44.8 million a year earlier. The company experienced a negative adjusted EBITDA of $(4.2) million and a gross profit margin of 25%. Despite these challenges, Glass House reiterated its full-year biomass production forecast of approximately 1 million pounds.
Read more →-GLAS
May 6, 2026Glass House Brands Announces Application for DEA Registration of Certain Medical Operations
Glass House Brands announced it has applied for DEA registration of its California-licensed medical cannabis operations. This follows the recent rescheduling of medical cannabis to Schedule III, allowing for an expedited registration process. The company will discuss this development and its financial results during an investor call on May 13, 2026.
Read more →About Glass House Brands Inc.
BIOPHARMAWATCH ELITE
Trade the next GLAS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime